Potential of gamma/delta T cells for solid tumor immunotherapy

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Gamma/delta T (γδ T) cells exhibit MHC-independent antigen recognition, crucial for tumor cell interactions.
• These cells are a promising cell therapy for cancer due to their unique cytotoxic mechanisms.

Purpose of the Study:

• To review human γδ T cell subtypes, functions, and regulatory effects on solid tumors.
• To explore γδ T cell involvement in tumorigenesis, migration, and potential therapeutic targets.
• To assess the clinical potential and challenges of γδ T cell-based immunotherapies.

Main Methods:

• Comprehensive literature review on γδ T cell biology and cancer immunotherapy.
• Analysis of mechanisms including MHC-independent recognition, apoptosis, and immune checkpoint pathways.
• Evaluation of clinical trial data for γδ T cell therapy products, including CAR γδ T cells.

Main Results:

• γδ T cells interact with solid tumors via MHC-independent pathways.
• Therapeutic targets identified include FAS/FASL, BTN3A-BTN2A1 complexes, and interactions with other immune cells.
• Chimeric antigen receptor (CAR) γδ T therapy shows promising preclinical results but faces manufacturing and clinical hurdles.

Conclusions:

• γδ T cell immunotherapy holds significant potential for cancer treatment.
• Standardized protocols and further research are essential to overcome clinical challenges and optimize patient outcomes.
• Long-term side effects of CAR T cells require thorough investigation.